Method for inducing reprogramming of alveolar type 1 cell into alveolar type 2 cell using Dasatinib
Dasatinib-based medium composition facilitates the reprogramming of type 1 alveolar cells into type 2 alveolar cells within airway organoids, addressing the scarcity and culturing challenges, enabling efficient production of physiologically active type 2 alveolar cells.
Patent Information
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- THE CATHOLIC UNIV OF KOREA IND ACADEMIC COOP FOUND
- Filing Date
- 2023-09-15
- Publication Date
- 2026-07-21
AI Technical Summary
The limited availability and difficulty in culturing type 2 alveolar cells (AT2 cells) due to their tendency to adopt a phenotype similar to type 1 alveolar cells (AT1 cells) in 2D culture, making it challenging to obtain sufficient numbers for research and applications.
A culture medium composition containing dasatinib, a tyrosine kinase inhibitor, is used to reprogram type 1 alveolar cells (AT1 cells) into type 2 alveolar cells (AT2 cells) within airway organoids, bypassing the need for overexpression of signaling proteins and transcription factors via viruses.
Efficient production of functional type 2 alveolar cells by directly reprogramming type 1 alveolar cells within organoids, overcoming the limitations of traditional methods and ensuring cells with physiological activity similar to actual tissue.
Smart Images

Figure 112023102640642-PAT00005_ABST